Page 173 - 2019秋季手冊內頁-ebook測試
P. 173
・Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study
・Novel Combination: IL-2 Combination
・A pilot study of engineered adenovirus ONCOS-102
in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma
